Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

Angiogenesis inhibition with sunitinib, a multitarget tyrosine kinase inhibitor of the vascular endothelial growth factor receptor, is associated with hypertension and cardiac toxicity, of which the underlying pathophysiological mechanism is unknown. We investigated the effects of sunitinib on blood pressure (BP), its circadian rhythm, and potential mechanisms involved, including the endothelin-1 system, in 15 patients with metastatic renal cell carcinoma or gastrointestinal stromal tumors. In addition, we investigated in rats the effect of sunitinib on BP, serum endothelin-1 levels, coronary microvascular function, cardiac structure, and cardiac mitochondrial function. In patients, BP increased by ≈15 mm Hg, whereas heart rate decreased after 4 weeks of treatment. Furthermore, the nocturnal dipping of BP diminished. Plasma endothelin-1 concentration increased 2-fold (P<0.05) and plasma renin decreased (P<0.05), whereas plasma catecholamines and renal function remained unchanged. In rats, 8 days of sunitinib administration induced an ≈30-mm Hg rise in BP, an attenuation of the circadian BP rhythm, and a 3-fold rise in serum endothelin-1 and creatinine, of which all but the rise in creatinine reversed after sunitinib withdrawal. Coronary microvascular function studies after 8 days of sunitinib administration showed decreased responses to bradykinin, angiotensin II, and sodium nitroprusside, all normalizing after sunitinib withdrawal. Cardiac structure and cardiac mitochondrial function did not change. In conclusion, sunitinib induces a reversible rise in BP in patients and in rats associated with activation of the endothelin-1 system, suppression of the renin-angiotensin system, and generalized microvascular dysfunction.

[1]  H. Smeets,et al.  Patients with Leber hereditary optic neuropathy fail to compensate impaired oxidative phosphorylation. , 2010, Biochimica et biophysica acta.

[2]  J. Granger,et al.  Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant Rats , 2010, Hypertension.

[3]  S. Sleijfer,et al.  Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects , 2009, Journal of hypertension.

[4]  S. Davidsen,et al.  ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats , 2009, Journal of cardiovascular pharmacology.

[5]  B. Jessen,et al.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  D. Nochy,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[7]  A. Danser,et al.  Effects of angiotensin II and its metabolites in the rat coronary vascular bed: is angiotensin III the preferred ligand of the angiotensin AT2 receptor? , 2008, European journal of pharmacology.

[8]  S. Wedge,et al.  Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy , 2008, Clinical Cancer Research.

[9]  S. Oudard,et al.  Home blood-pressure monitoring in patients receiving sunitinib. , 2008, The New England journal of medicine.

[10]  David Zurakowski,et al.  Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib , 2007, The Lancet.

[11]  H. Izzedine,et al.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  D. McDonald,et al.  Mechanisms of adverse effects of anti-VEGF therapy for cancer , 2007, British Journal of Cancer.

[13]  R. A. Etten,et al.  Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.

[14]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  H. V. van Beusekom,et al.  Mitochondrial adaptations within chronically ischemic swine myocardium. , 2006, Journal of molecular and cellular cardiology.

[16]  H. Gelderblom,et al.  VEGFR2 blockade in patients with solid tumors: Mechanism of hypertension and effects on vascular function. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Flaherty,et al.  Mechanisms of hypertension associated with BAY 43-9006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Ping,et al.  Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transition. , 2005, American journal of physiology. Heart and circulatory physiology.

[19]  J. Ménard,et al.  Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats , 2005, Journal of hypertension.

[20]  T. Spector,et al.  Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies , 2004, The New England journal of medicine.

[21]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[22]  P. Saxena,et al.  Restored Capillary Density in Spared Myocardium of Infarcted Rats Improves Ischemic Tolerance , 2002, Journal of cardiovascular pharmacology.

[23]  J. Saris,et al.  Prorenin Accumulation and Activation in Human Endothelial Cells: Importance of Mannose 6-Phosphate Receptors , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  A. J. Man in 't Veld,et al.  Optimal collection and storage conditions for catecholamine measurements in human plasma and urine. , 1993, Clinical chemistry.

[25]  A. J. Man in 't Veld,et al.  Simultaneous determination of catecholamines and dobutamine in human plasma and urine by high-performance liquid chromatography with fluorimetric detection. , 1992, Journal of chromatography.

[26]  M. Schalekamp,et al.  Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. , 1986, The Journal of clinical endocrinology and metabolism.

[27]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[28]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Gathiram,et al.  Immunolocalisation and endothelin-1 values In pre-eclampsia: an immunocytochemical study. , 2001, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.